Quarterly results round-up: Allergan gets device lift with post-PIP breast implant growth, CareFusion and BD sales up but profits down
This article was originally published in Clinica
Executive Summary
Allergan succeeded in growing its medical devices division – albeit a modest 1% increase, at $226.2m – as double-digit growth in its breast aesthetics division boosted ailing sales of its obesity intervention and facial aesthetics products.